In conclusion, in this pilot study, 10 female ME/CFS patients with high symptom burden and long disease duration received the anti-CD38 antibody daratumumab to target long-lived plasma cells, with subsequent reductions of serum IgG levels. This evidence concerns the gene CD38 and myalgic encephalomeyelitis/chronic fatigue syndrome.